Literature DB >> 8395142

Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS.

O Lortholary1, M C Meyohas, B Dupont, J Cadranel, D Salmon-Ceron, D Peyramond, D Simonin.   

Abstract

PURPOSE: Acquired immunodeficiency syndrome (AIDS)-associated invasive aspergillosis (IA) is a rare condition, which is mainly reported as isolated cases either antemortem or at autopsy. The role of AIDS itself is controversial, because many of the reported patients exhibited the classic risk factors such as neutropenia and steroid therapy. The aims of this study were to report 33 patients with IA during AIDS and their outcome, focusing on the risk factors and the value of diagnostic procedures. PATIENTS AND METHODS: Thirty-three patients from 17 different medical centers in France were retrospectively included in the study. For pulmonary IA, we defined two types of patients: those with "confirmed IA," describing all the patients with histologically proven disease, and those with "probable IA," who had the development of a new pulmonary infiltrate on chest radiograph and a positive bronchoalveolar lavage (BAL) fluid culture for Aspergillus species without identification of other pathogens. For extrapulmonary IA, the diagnostic criteria included both positive histology and culture.
RESULTS: Of the 33 cases included in this series, 91% were recorded during the last 3 years (1989 to 1991), suggesting that aspergillosis is an emerging complication in AIDS. Approximately 50% of the patients did not exhibit any classic risk factor, i.e., neutropenia and steroid treatment; almost all patients had a CD4 cell count less than 50/mm3. The mycologic culture from BAL was the method of choice for the diagnosis of invasive pulmonary disease because it was known to correlate well with histologic findings obtained either antemortem or postmortem. Of 28 patients with a positive BAL culture for Aspergillus, 15 underwent a biopsy or autopsy and 14 were positive at histology. Serum antigen detection was positive in only 4 of 16 tested patients. Clinical and radiologic signs did not differ from those observed in neutropenic patients without human immunodeficiency virus, except for the higher incidence of neurologic complications in AIDS. Interestingly, we observed three cases of invasive necrotizing tracheobronchial aspergillosis with acute dyspnea and wheezing. The use of amphotericin B (0.5 mg/kg/d) and/or itraconazole (200 to 600 mg/d) was most often unsuccessful. Only four patients experienced clinical and radiologic improvement. The mean interval between the diagnosis of IA and death was 8 weeks (range: 3 days to 13 months).
CONCLUSIONS: This study suggests that aspergillosis is an important life-threatening condition in the advanced stage of AIDS. It requires an early diagnosis with BAL fluid culture and careful therapeutic evaluation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395142     DOI: 10.1016/0002-9343(93)90258-q

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  31 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

Authors:  A Espinel-Ingroff; M Bartlett; V Chaturvedi; M Ghannoum; K C Hazen; M A Pfaller; M Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

Authors:  Shawn A Messer; Daniel J Diekema; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

Review 4.  Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome.

Authors:  Maria N Gamaletsou; Blandine Rammaert; Marimelle A Bueno; Brad Moriyama; Nikolaos V Sipsas; Dimitrios P Kontoyiannis; Emmanuel Roilides; Valerie Zeller; Roberta Prinapori; Saad J Taj-Aldeen; Barry Brause; Olivier Lortholary; Thomas J Walsh
Journal:  J Infect       Date:  2013-12-27       Impact factor: 6.072

5.  Aspergillus infection of the epiglottis in a HIV positive patient.

Authors:  P Sriskandabalan; R B Roy
Journal:  Genitourin Med       Date:  1996-12

6.  Fungicidal activity of cecropin A.

Authors:  A J DeLucca; J M Bland; T J Jacks; C Grimm; T E Cleveland; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  N-acetylcysteine inhibits germination of conidia and growth of Aspergillus spp. and Fusarium spp.

Authors:  A J De Lucca; T J Walsh; D J Daigle
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 8.  Aspergillus endocarditis: a case of near complete left ventricular outflow obstruction.

Authors:  Rizwan Q Attia; Justin L Nowell; James C Roxburgh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-27

9.  E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.

Authors:  Ana Espinel-Ingroff; A Rezusta
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

10.  Management of pulmonary aspergillosis in AIDS: an emerging clinical problem.

Authors:  J J Keating; T Rogers; M Petrou; J D Cartledge; D Woodrow; M Nelson; D A Hawkins; B G Gazzard
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.